n a bit more deliberate than Jazz, but is coming along nicely. Antares started its royalty deals with a gel based platform, one being a royalty deal with Actavis, Inc. (NYSE: ACT) (formely Watson Pharma) for topical oxybutynin gel. Oxybutynin…
Tag: ATRS
4 Top Small Cap Biotech Acquisition Targets
Today, I list small cap companies I believe are top acquisition targets for large pharma. I combine speculation, rumors and buzz I am hearing, and company financial position as a few factors for consideration. Buy-outs are hard to predict in…
Biosciences Delivery Systems+ Antares Chart Update: 5/25/13 $BDSI, $ATRS
My opinion on Antares BDSI pasy trading action and for the future.
I bought Antares @ $3.95, I see a move to $4.35 short term
I bought Antares @ $3.95, I see a move to $4.35 short term. I think from tomorrow to beginning of next week, we see the move. From above, we can clearly see a tightening wedge forming in the chart. I…
Weekend update with some charts, Market forecast and opinion. (VIDEO)
Weekend update with some charts, $AVEO $ATRS $ARNA $ACRX briefly covered. Market forecast and opinion. YouTube Video
Valeant Acquires Obagi, Which Biotechs Are Next?
Yesterday, Obagi Medical Products (OMPI) was acquired by Valeant Pharmaceuticals (VRX) for $19.75 a share in an all cash deal. Last summer I covered in depth, acquisition rumors regarding Obagi. At the time, good private sources of mine confirmed that…
Strong Small Cap Biopharma Catalyst Trades And Investments For Consideration
Trading biophama stocks before a catalyst event, if done correctly, can be a very profitable proposition. Some traders and investors who enjoy bringing more risk into play often times will hold through the actual catalyst event. While this does bring…
ArQule: A Strong Speculation BioPharma Poised For A Quick Move Up On Near Term Catalyst
ArQule (NASDAQ: ARQL) ArQule engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Its lead product candidate Tivantinib (ARQ 197) is an inhibitor of the c-Met receptor tyrosine kinase, which is in Phase…
Video Blog: Hurricane Sandy Aftermath + Promised Commentary on $ATRS
Video Blog: Hurricane Sandy Aftermath + Promised Commentary on $ATRS: During this holiday season, please remember those who are far less fortunate than us. These people really need our help — anything helps, so please donate what you can. Also,…
Small Cap Bio-Pharmas For Possible Long Side Trades
With some added confidence shown by investors yesterday, it’s a good time to look at some “risk on” small cap bio-pharma stocks that I feel offer good upside for both swing trades and longer term holds. However, with the looming…
